Fred Hutchinson Cancer Research Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
99
About the Report
About the Report
Summary
Fred Hutchinson Cancer Research Center (Fred Hutchinson), a subsidiary of National Comprehensive Cancer Network, is a nonprofit organization which conducts research on the prevention, diagnose and treatment of cancer, HIV/AIDS and other life threatening diseases. It conducts research on various diseases such as cervical cancer, colorectal cancer, crohn's disease, cystic fibrosis, esophageal cancer, influenza, kaposi sarcoma, barrett's esophagus, brain tumors, breast cancer, leukemia, lung cancer, lymphoma, malaria, melanoma, sickle cell disease, wilms tumor, skin cancer, merkel cell carcinoma, multiple myeloma, multiple sclerosis, myelodysplastics syndrome, opportunistic infections, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rheumatoid arthritis, sarcoma, scleroderma, and liver cancer, among others. Fred Hutchinson's clinical research division provides laboratory and patient-oriented research to understand the mechanisms that drive cancer and other human diseases. The organization also offers various education and training services for undergraduate, graduate, and high school students. Fred Hutchinson is headquartered in Seattle, Washington, the US.
Fred Hutchinson Cancer Research Center-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Fred Hutchinson Cancer Research Center, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fred Hutchinson Cancer Research Center, Medical Devices Deals, 2012 to YTD 2018 10
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 18
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 19
Juno Therapeutics Enters into Research Agreement with FHCRC 20
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 21
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 22
Licensing Agreements 23
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 23
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 24
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 25
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 26
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 27
Juno Therapeutics Enters into Licensing Agreement with FHCRC 28
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 29
Fred Hutchinson Cancer Research Center-Key Employees 31
Fred Hutchinson Cancer Research Center-Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Government and Public Interest 33
Sep 24, 2018: Hyundai Hope on Wheels presents Fred Hutchinson Cancer Research Center with USD 300,000 Hyundai Hope scholar grant to support pediatric cancer research 33
Sep 14, 2018: Washington's Andy Hill Cancer Research Endowment awards USD 1.5M to 3 Fred Hutch researchers 34
Aug 20, 2018: Dr. James Dai receives USD 2.1M NCI grant for cancer biomarker research 36
Aug 15, 2018: Fred Hutch receives USD 1.26M grant to boost science-education efforts 37
Jul 31, 2018: Improving cancer vaccines with T-cell programming nanoparticles 38
Jul 02, 2018: Nanoparticles open doors to cancer-fighting CAR T cells 39
Jun 13, 2018: HICOR receives 2-year, USD 250K award to boost patient engagement 41
Jun 11, 2018: ASCO endorses integrative oncology guidelines for breast cancer patients 42
May 31, 2018: 3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant 45
May 31, 2018: Biologics and biosimilars step onto the cancer therapy stage 46
May 30, 2018: Nanoparticles take immunotherapy in new direction 49
May 23, 2018: Gene editing shows promise for sickle cell and related disorders 50
Apr 20, 2018: Gene-edited stem cells reduce HIV risk in non-human primates 51
Apr 17, 2018: First human antibody found to block Epstein-Barr virus 52
Apr 12, 2018: With approval of new CMV drug for transplant patients, a legacy continues 54
Mar 29, 2018: Dr. Sita Kugel receives USD 100K grant to study pancreatic neuroendocrine tumors 57
Mar 19, 2018: Newly described human antibody prevents malaria in mice 58
Mar 19, 2018: New antibody and unique binding site offer possible paths to malaria prevention 59
Mar 16, 2018: Jump-starting innovative projects exploring pathogen-associated cancers 61
Mar 15, 2018: USD 7 million grants boost functional genomics team science 62
Mar 15, 2018: A roadmap for precision colorectal cancer screening 63
Mar 13, 2018: Study uncovers new proteins involved in regulating muscular dystrophy-linked gene 66
Mar 09, 2018: Health Disparities Research Center awards pilot grants for 2 new public health projects 68
Mar 07, 2018: Dr. Alice Berger receives USD 200K grant for lung cancer research 70
Feb 26, 2018: New technological platform opens unexplored world of tiny proteins 71
Jan 25, 2018: Microbiome research refines HIV risk for women 73
Dec 11, 2017: Health disparities may affect end-of-life experiences of minority blood cancer patients 75
Nov 14, 2017: Targeted therapies push metastatic prostate cancer in new directions 77
Nov 06, 2017: First systematic study of infections after CAR T-cell therapy 79
Oct 17, 2017: Three of the Most Deadly Cancers Get Critical Funding for Research 80
Aug 30, 2017: New nanoparticles make targeted, temporary gene therapy possible 81
Aug 17, 2017: Kleberg Foundation grant to support clinical trial for leukemia patients 84
Jun 16, 2017: Dr. Eduardo Mendez receives USD 2.2M in NIH funding for targeted therapies for head-and-neck cancers 86
Jun 08, 2017: Fred Hutch epidemiologists receive USD 2.5M grant for first-ever study of therapeutic use for HPV vaccine 88
Jun 01, 2017: New library of HIV mutants could inform vaccine design 89
Product News 92
Dec 21, 2017: Designing protein drugs for cancer: New method pinpoints a promising candidate 92
Dec 06, 2017: The Leukemia & Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer 93
10/13/2017: New markers could identify patients most at risk of brain damage from CAR T cell immunotherapy 95
Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects 96
Other Significant Developments 98
May 01, 2018: Dr. Reema Jain developing methods to isolate, manipulate blood stem cells for T-cell therapy 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
List of Figure
List of Figures
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fred Hutchinson Cancer Research Center, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fred Hutchinson Cancer Research Center, Deals By Therapy Area, 2012 to YTD 2018 9
Fred Hutchinson Cancer Research Center, Medical Devices Deals, 2012 to YTD 2018 10
Fred Hutchinson Cancer Research Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 18
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 19
Juno Therapeutics Enters into Research Agreement with FHCRC 20
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 21
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 22
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 23
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 24
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 25
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 26
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 27
Juno Therapeutics Enters into Licensing Agreement with FHCRC 28
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 29
Fred Hutchinson Cancer Research Center, Key Employees 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.